Humana (NYSE:HUM) had its price target raised by analysts at Wolfe Research from $300.00 to $325.00. They now have an "outperform" rating on the stock.
Humana Expands Cancer Care for Medicare Advantage Members Through Atlas Oncology Partnership [Yahoo! Finance]
Humana Expands Cancer Care for Medicare Advantage Members Through Atlas Oncology Partnership
CenterWell Pharmacy to Dispense Obesity Management Medications as Part of New, Employer-Focused Program
Humana Inc. to Release Fourth Quarter 2025 Results on February 11, 2026